Sarepta (SRPT) grants director 16,875 RSUs with one-year vesting

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. reported that director Deirdre P. Connelly acquired 16,875 shares of common stock through a grant of restricted stock units (RSUs) at $0.00 per share as director compensation. Following this award, she directly holds 22,100 shares of Sarepta common stock.

The footnote explains that each RSU represents one share of common stock and will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting that occurs at least 50 weeks after the prior year’s meeting. This is a stock-based compensation grant rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Connelly Deirdre P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,875	$0.00	--

Holdings After Transaction: Common Stock — 22,100 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 16,875 shares Grant price: $0.00 per share Total shares after grant: 22,100 shares

3 metrics

RSUs granted 16,875 shares Common Stock RSU award to director on 2026-06-04

Grant price $0.00 per share Equity compensation grant price for RSUs

Total shares after grant 22,100 shares Director Deirdre Connelly direct holdings following transaction

Key Terms

restricted stock units ("RSUs"), vest, annual meeting of stockholders

3 terms

restricted stock units ("RSUs") financial

"The Reporting Person was granted restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vest financial

"The RSUs will vest on earlier of the one-year anniversary of the date of grant"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"and the next annual meeting of stockholders which is at least 50 weeks after"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Connelly Deirdre P

(Last) (First) (Middle)

215 FIRST STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		16,875	A	(1)	22,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Deirdre Connelly	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Sarepta Therapeutics (SRPT) report in this Form 4?

Sarepta reported a grant of 16,875 restricted stock units to director Deirdre P. Connelly. Each RSU represents one share of common stock, increasing her direct holdings to 22,100 shares after the award.

How many Sarepta (SRPT) shares did director Deirdre Connelly receive and at what price?

Deirdre Connelly received 16,875 shares of Sarepta common stock through an RSU grant at $0.00 per share. This reflects a stock-based compensation award, not an open-market purchase of shares.

When do the newly granted Sarepta (SRPT) RSUs to Deirdre Connelly vest?

The RSUs vest on the earlier of one year from the grant date or the next annual stockholder meeting. That meeting must occur at least 50 weeks after the immediately preceding year’s annual meeting, according to the footnote.

What is Deirdre Connelly’s total Sarepta (SRPT) shareholding after this Form 4 transaction?

After the grant, Deirdre Connelly directly holds 22,100 shares of Sarepta common stock. This total includes the 16,875 shares underlying the newly awarded restricted stock units reported in the filing.

Is the Sarepta (SRPT) Form 4 transaction an open-market buy or a compensation grant?

The Form 4 shows a compensation-related grant of restricted stock units, not an open-market purchase. The transaction code is “A,” and the footnote explains these RSUs are an equity award with vesting conditions for the director.